South Beach Skin Lab Reviews (Latest Report): Repair & Release Cream—Does It Work?
PLACEHOLDER, March 10, 2025 (GLOBE NEWSWIRE) -- The Repair & Release Cream from the South Beach Skin Lab is currently the best-selling anti-aging cream. What's so special about this latest anti-aging cream? Well, the news is that this is the only cream you need in your cabinet. It oozes with powerful peptides and botanical ingredients that work in synergy to reverse wrinkles and reduce sagging while increasing collagen and elasticity. Learn More From The South Beach Skin Lab Official Website >>In this South Beach Skin Lab review, we will know how this age support cream actually works! It is formulated by Dr. Ryan Shelton, and the South Beach Skin Lab promise is to give younger-looking skin in just 20 seconds a day! While the press news is explaining how Dr. Ryan Shelton is redefining the anti-aging formula with potent peptides as Proage™ and Matrixyl Synthe 6™ that are bound to banish those wrinkles and present you a fortified skin- in this review on South Beach Skin Lab Repair and Release cream we explain what to expect; plus, insider secrets on how to get promotional updates and offers.
In this review on South Beach Skin Lab, we will also expose the shallow practices of many well-known cosmetic companies, plastic surgeons, and even the governing agencies that regulate them. But don't just take it from us, as we will also be sharing with you real South Beach Skin Lab customer reviews in this editorial version. So, without further ado, let's jump to the point, and here it goes regarding everything you need to know about this new hottest anti-aging product.
What is South Beach Skin Lab Repair and Release Cream?South Beach repair and release cream by Dr. Ryan Shelton is a newly advanced peptide formula that fights stubborn fine lines and wrinkles and that even within a month of the application. It is an intense formula that regenerates collagen and other essential amino acids and proteins and boosts collagen and elastin naturally.
Based on incredible new research from the Journal of Cosmetic Science, I will show you how this amazing new method works, using protein from your own body to begin restoring your skin's youthful appearance in as little as 30 days—taking your skin from loose, saggy, and dull to tight, lifted, and vibrant without doing so much as lifting a finger. It won't require you to use harsh chemicals like Botox or resort to barbaric surgeries like facelifts and neck tucks. This simple trick can even be done from the comfort of your own home. And it is so dirt cheap, and it might as well be free.
Now, you might be feeling skeptical, and trust me, it is normal. But the truth is, this 100% natural solution called the South Beach Lab Repair and Release Cream goes against everything mainstream cosmetic companies and big pharma want you to believe about anti-aging. Many of the reasons you have been told by doctors and cosmetic ads about why your skin wrinkles are not only misleading but are actually dead wrong, and you will be shocked to find out the real reason has nothing to do with your genetics, your age, or your skin type.
But it instead is the result of a poorly understood mechanism that right this second is instructing your brain to stop producing a simple protein that controls aging. And by simply tricking your brain into turning this protein "back on," you can allow this dormant compound that still exists in your body to start producing fresh, natural, and anti-aging cells—just as it did in the past. It doesn't matter if you are 39 or 79, have dry skin or oily skin.
If you have tried everything already and have a large number of wrinkles, South Beach Skin Lab face cream will effortlessly tighten and smooth every square inch on your face and neck. Leaving all your friends and family to wonder what your secret is. In this sort but information-packed review, we will tell exactly how, you too, can safely and easily turn on this protein for yourself.
=>(SPECIAL OFFER) Get South Beach Skin Lab with an Exclusive Discount Price from Official Website!
How South Beach Skin Lab Repair Cream Work?So, how does South Beach Skin Lab Repair and Release cream work? By now, we have shared that it is created by Dr. Ryan Shelton.
Dr. Ryan Shelton has dealt with well over 10,000 women at my clinic with breakdown cases regarding their skin aging embarrassments. He had seen it all. He even spent nearly a decade developing anti-aging formulas at the University Compounding Pharmacy in San Diego. He had solved advanced cases where women developed deep wrinkles around both the eyes and mouth. Sometimes the forehead brow gets furrowed like a rolling wave, and the skin around the neck and décolleté had almost detached itself from the jawline.
Some clients were so much in a desperate state that they considered Botox and plastic surgery.
1 in every 10,000 cosmetic surgeries ends in death. Is that how you want to leave your kids? The truth is there is a dirty little secret in the skincare industry no one really talks about. The problems being sold to you are not meant to fix your problem. They are only meant to treat the symptoms. There is the only thing that actually causes your skin to wrinkle. That is a breakdown in your skin's structural proteins.
There are lots of different proteins in our skin, which are known scientifically as amino acids. These amino acids make up our skin's complexion. You may have heard some of them, such as keratin, actin, and laminin. But there are only two that really matter for preventing wrinkles, and these are Collagen and Elastin.
Elastin is the amino acid in your body that acts like an elastic band, giving your skin the ability to snap back into place after it stretches. Without it, your skin starts to sag and lose its shape. On the other hand, collagen makes up about 71% of the amino acids in your skin, providing it with its fullness, supple touch, and vibrance. When combined, they are what give your skin its youthful look—and this brings us to the South Beach Skin Lab repair cream ingredients that do the work for bright, beautiful skin in no time!
South Beach Skin Lab Repair and Release Cream Ingredients
When writing this review on South Beach Skin Lab, we have counted A to Z of the South Beach Skin Lab ingredients as per the South beach repair and release cream label. As it turns out, the key ingredients are peptides, collagen, and elastin. The amino acids work as the skin-lifting activators, and hence in the label, you will find that it contains a list of peptides.
No wonder it is a high-quality anti-aging cream that exceeds our expectations. Because the South Beach Skin Lab Repair and Release cream also contain certain ingredients that are only found in high-end products. The repair and release cream contains peptides called acetyl octapeptide-3, acetyl tetrapeptide-5, palmitoyl tripeptide-5, palmitoyl dipeptide-5, and palmitoyl tripeptide-38—no wonder it boosts the collagen and the elastic at the first application of the cream.
Side by side, it contains a range of premium essential oils such as Cocos Nucifera (coconut) oil, sea buckthorn fruit oil, Argania Spinosa (argan) kernel oil, shea butter, seed butter, and other ones to work beyond the surface level and uncover the radiant skin.
The first ingredient present in the South Beach Skin Lab Repair and Release cream is almost in every formula. It is called a Neurotransmitter peptide, or neuropeptide for short. It was specifically added to prevent the breakdown of the Elastin that we discussed earlier. Some researchers even call it "Botox in a Bottle." It works by sending a signal to your brain to block the muscle contractions that break down elastin in your skin.
You see, every time you smile, laugh, or frown- your face makes an expression in the same exact place. Over time, this breaks down the elastin structure in these spots causing a wrinkle. By applying a neuropeptide to the affected area, we can trick the brain into stopping the skin from making these movements in the first place and preventing future wrinkles from developing or existing wrinkles from getting worse. This fixes the skin from suffering further Elastin breakdown.
The next ingredients of the South Beach Skin Lab Repair and Release cream restores collagen production. One of the studies has combined a second type of Peptide and saw even more dramatic results. It was called a Signal Peptide. Researchers call it this because it literally sends a signal to your brain, giving it instructions on what proteins to produce in your skin. By doing this, signal peptides can once again trick the brain into producing amino acid proteins like collagen. Even after your body has stopped producing it naturally! Thus this anti-aging solution carries a broad spectrum of peptides that are bound to demonstrate remarkable benefits and revitalize your skin inside out.
Does South Beach Skin Lab Work?
For once again, does South Beach Skin Lab Repair and Release cream really work? After going through the list, we can clearly understand that it is backed by science. Dr. Ryan Shelton's South Beach Skin Lab Repair and Release cream is proven to work.
Over 52,063 people have used this groundbreaking solution, and the south beach skin lab's video is starting to go viral. If you are interested in learning how to take years off your appearance in the next 30 days, you must read this full in-depth review on South Beach Skin Lab Repair and Release cream.
Many studies even found that the chemicals used in making these moisturizers, such as BPAs, Sulfates, and Parabens, are now known to be "carcinogenic." That means they can contribute to causing cancer! It's no wonder any of these solutions work. So, you might as well have saved a few hundred dollars and bought a bottle of Jergens at Walgreens.
The problem is after you turn 18, your body's collagen and elastin production decreases by about 1% per year. When you are 50 years old, the collagen and the elastin receptors in your body mostly begin to shut off. That's exactly why none of the things you have been trying make any difference. They weren't designed to address these problems but only to mask them with temporary results.
Contrary to these, this essential anti-aging formula from the South Beach Skin Lab handles the breakdown of collagen and elastin and turns it back on. The biggest benefit of the South Beach Skin Lab face cream is that it restores collagen and elastin production.
The peptide is something that is going viral not in Europe but also on Facebook. The peptide is a potent compound that is used for muscle regeneration in athletes for years. Who would have thought Peptide could also be used for skin regeneration? There is still no product out there that uses peptides like that of the South Beach Skin Lab repair and release cream for anti-aging.
Some foods are high in peptides, such as whole grains and beans. But the concentrations of these food ingredients are nowhere near high enough to achieve the results. However, some French products have peptides in them, but the products are extremely expensive and only in their raw ingredient form. In some cases, they are like $600 a milligram.
At University Compounding Pharmacy in San Diego. No place in America utilizes the cutting edge of anti-aging technology as the University of Compounding Pharmacy in San Diego. The high-tech equipment allowed them to research and create the best-of-the-best anti-aging formula, the South Beach Skin Lab Dr. Ryan Shelton's formula—that other labs had only dreamed of doing.
It turns out that Peptides are actually very complex structures. At their most basic level, a peptide is just an amino acid, or as we explained, it is commonly known as a protein. But the thing that makes peptides special compared to other proteins is that when they are applied directly, they have the ability to "talk" to the receptors in the skin. Much the same way an antibiotic can tell the white blood cells in your body how to kill the infection. Peptides can do the same thing for your skin!
The problem is while peptides can be used to remove sagging, crow's feet, patches, dark spots, and deep wrinkles, there are a lot of different compounds. So you have to know which Peptide will fix which issue. For skin that has aged drastically, the creators had to find an extremely effective combination of peptides to heal the damage. Dr. Ryan delved deeper into the studies to find the exact formulas that the lab had been using.
In fact, the study found that when 23 female volunteers aged from 42 to 67 years old used a signal peptide cream similar to the South Beach Skin Lab Repair and Release cream's formula twice a day on half of their face. After just two months, there was an incredible 39% overall reduction in the depth of their wrinkles. But that wasn't all.
Scientists found that signal peptides could reduce skin roughness by 16%, improve skin tone by 15%, lift sagging skin by 17%, and even heal damage from U.V. rays by 20%. Not only could it help prevent future wrinkles, but they also repair wrinkles that already exist, and that's how South Beach Skin Lab Repair and Release cream works, actually.
=>(LOWEST PRICE GUARANTEED) South Beach Skin Lab For The Lowest Price From Official Website!
South Beach Skin Lab Repair and Release Cream Pros and Cons
Before shopping for Anti-aging products, we must understand what they are and why we pick the products based on the pretty labels on the outside of the box instead of what's actually inside? On the contrary to this, in this review on South Beach Skin Lab, we have shared that it is specifically a peptide anti-aging face cream that does the work in rejuvenating your skin inside and out.
Just as every other cosmetic product, South Beach Skin Lab has a certain set of pros and cons attached to it. However, the good sides of this repair and release cream clearly outweigh the drawbacks. That is why in this section on South Beach Skin Lab products review, we share the South Beach Skin Lab repair and release cream pros and cons:Formulated for deep wrinkle repair
Provides morning and nighttime moisturizer
Heals damaged skin from U.V. rays
Sustainably sourced ingredients
Lab Tested
Suitable for all skin types
South Beach Skin Lab return policy is very transparent
100% Money Back GuaranteedLimited stock
Not available from physical stores
Only available exclusively at the official website.
South Beach Skin Lab Repair and Release Cream Customer Reviews
Now comes the most interesting part, and that is there any South Beach Skin Lab complaints? That is why we have undergone thousands of reviews, and the good news is there are still no such complaints. So, in this section, we present to you three of the best south beach lab reviews from the website-
"My daughter was getting married the next summer. Right then and there, I made a promise to myself that I am going to make a change. There is no way I am going to show up to see all my friends and family I haven't seen in years, looking like a withered-up old prune. The big day had arrived, and I simply kept myself busy—you know what moms do at their daughter's wedding. But what should have one of the proudest moments of my life became one of the worst. The priest called me the "grandmother" of the bride! Everyone was staring at me, and it felt like a thousand eyeballs were burning a hole in my head. All the negative thoughts I had been feeling came swarming back in like a tsunami. Desperate, me soon came across South Beach Skin Lab Repair and Release cream. By my research, the South Beach Skin Lab products have a good reputation. Well, it's been only a week that I am using it, and I wish I would have used it before my daughter's wedding. My skin is radiant now, and just within a week, I find my skin more relaxed—I think it is working, but the only complaint is that it contains a very small amount." –
"I tried everything—balms, serums, moisturizers, scrubs, peels, and what not! But the more and more products I tried, the more and more depressed I became as nothing seemed to make a lick of difference. One of the most expensive creams even caused me to break out like a teenager! It was basically just plain old moisturizers in pretty boxes. But I have been using South Beach Skin Lab repair and for a little over a month, and I am happy with the results. Not a single breakout and I will most likely order it again."
"I like this product because it really helps and also it is so moisturizing. This will be my cream forever. The fact is, the older you are, the more appreciation you will have for this repair cream. I am using it on wrinkles around my face, and the crow's feet around my eyes are noticeably minimizing. It is a fantastic hydrating cream- that I must say!"
=>Check More Reviews On The Official Website! Visit Now & Check Your Amazing Offers!!
South Beach Skin Lab Repair and Release Cream Where to Buy
Now, the question is where to buy South Beach Skin Lab Repair and Release cream? Are South Beach Skin Lab Repair and Release Creams available at the store? Nope, and that's the only South Beach Skin Lab complaint we got so far. However, there is nothing to worry about because you can readily get it available on their official website.
By visiting the website, you will come across the shop store, and there you can place your South Beach Skin Lab Repair and Release cream order and get your product shipped right to your doorstep. According to South Beach Skin Lab reviews, you also get 50% off your first order when your shop it from the official website. We also urge you to visit the website because you get to read the real reviews for South Beach Skin Lab Repair and Release cream from there also get a 100% money-back guarantee for a full 30 days. Besides, there is a limited-time offer on all South Beach Skin Lab products right from the website.
South Beach Skin Lab Repair and Release Cream PriceSo, how much is South Beach Skin Lab Repair and Release cream? As it turns out, the South Beach Skin Lab Repair and Release cream costs only $59 for the USA user. Plus, you get a discount if you are ordering for the first time from their official website.
There is one important thing that we simply have to share with you, and that makes sense as to why South Beach Skin Lab Amazon is not a good idea. By visiting the website, you are entitled to amazing promotional features, and that includes South Beach Skin Lab discount code for almost all the South Beach Skin Lab products. If you are still not getting the South Beach Skin Lab coupon code, simply contact the South Beach Skin Lab customer service. South Beach Skin Lab address is shared with you right at the bottom of this article.
=>(HUGE SAVINGS TODAY) South Beach Skin Lab For The Lowest Price Right Now From The Official Website!
South Beach Skin Lab Reviews—Final Words
Finally, is South Beach Skin Lab Repair and Release cream good? We have explained why it is good and how good it is in tightening the skin and preventing sagging, and for that, we shared the South Beach Skin Lab ingredient that does the work. In this South Beach Skin Lab Repair and Release cream review, we also highlighted that why South Beach Skin Lab peptide cream is the only one you need in your cabinet.
If crow's feet appear across the eyes like cracks in the desert floor and if your lips look thin and frail—it doesn't have to be like this! It is time that you stop picturing yourself and your neck and decollate as if hanging like old curtains at a movie theater. You may try your best to feel positive, but there are times when you just can't feel beautiful anymore, and that is why we think that South Beach Skin Lab Repair and Release Cream is a must for your cabinet. This is the one single product that not only increases collagen production in your skin but also rejuvenates the skin with essential amino acids and peptides.
FAQs About South Beach Skin Lab Repair and Release CreamAnswer: Yes, South Beach Skin Lab is a legit company based in the U.S. You can get a thorough and in-depth idea simply by visiting their official website. South Beach Skin Lab is made in one of the most prestigious labs in Miami, U.S., the same lab that has been formulating many high-quality creams. It is made right here in the USA with American workers, and the lab was called South Beach Skin Lab.Answer: South Beach Skin Lab is a prestigious company, and there is nothing scam regarding the South Beach Skin Lab products. It turned out that way back in 1938, in an effort to protect consumers, U.S. President Franklin. D. Roosevelt established the Food, Drug, and Cosmetics Act.
In a huge oversight, he left open what is still considered one of the biggest legal loopholes in history. He had accidentally only given them the powers to regulate medical claims. This meant that as long as cosmetic products didn't claim to have any medical benefits, they could market almost anything they wanted! Unfortunately, this destroyed the majority of anti-aging research taking place in America. There was no longer any motivation for cosmetic companies to put out better products, and they continued to sell the same old junk at a huge profit margin.
There is actually a lawsuit for such blatant scams. In 1987, after being pressured by consumer advocate groups, the Food and Drug Administration tried to fix its rule to protect women from all misleading ads that were scamming them out of their hard-earned money.
They launched a lawsuit against a cosmetic company you may have heard of—Estee Lauder. The same Estee Lauder owns many of the trusted cosmetic brands in America, like Clinique, Aveda, and MAC Cosmetics. Estee Lauder's marketing had become so deceptive to women that it was now making medical claims that were completely untrue. Later, Estee Lauder gathered the cosmetics industry to lobby the government to drop the case.
Sadly, it worked. The U.S. District Court in 1989 left Estee Lauder and the cosmetics industry free to continue to operate with almost no regulations. This doesn't have to be with you. And you don't have to spend all your hard-earned money on buying snake oil formulas from 1938. So, South Beach Skin Lab repair and release cream is a legit and best anti-aging cream out there.Answer: For sure, this highly-concentrated super-hydrating and Peptide oozing anti-aging formula works. As a matter of fact, it is backed by science. One study on South Beach Skin Lab peptide cream states that it could produce a stunning 52% reduction in the depth of wrinkles in just 28 days. And amazingly, they found in multiple trials that they were 100% safe for human use.
Another study published in 2013 by Spring International in Switzerland showed that in a sample of 60 total subjects, the group that received a peptide cream similar to South Beach Skin Lab face cream once daily showed an anti-wrinkle effect of 48.9%. That was like peeling away ten years of wrinkles and sagging skin in only one month.
=>(LOWEST PRICE GUARANTEED) South Beach Skin Lab For The Lowest Price From Official Website!https://www.removethewrinkles.com/studies/syn-1.pdf
https://www.removethewrinkles.com/studies/arg-1.pdf
https://www.removethewrinkles.com/studies/matryx-1.pdf
https://blog.southbeachskinlab.com/Answer: The South Beach Skin Lab phone number is 1-877-557-6349, and the email address is info@southbeachskinlab.com. As per the website, the South Beach Skin Lab customer service is readily available 24/7. The South Beach Skin Lab address is also available on the website.
Read More: South Beach Skin Lab Reviews
About: HealthyRex
HealthyRex shares e-commerce and sales news, product reviews, and the latest news on various products.
Media Contact: admin@healthyrex.com
HealthyRex provides this review for informational purposes only. The information does not constitute advice or an offer to buy. Any purchase done from this story is done at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase done from this link is subject to the final terms and conditions of the website that is selling the product. The content on this release does not take any responsibility directly or indirectly.
Affiliate Disclosure:The links contained in this product review may result in a small commission to HealthyRex if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high-quality products.
Disclaimer:Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease.
Product support: info@southbeachskinlab.com
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cad298a-0062-47cc-ae2a-10395b045e29
https://www.globenewswire.com/NewsRoom/AttachmentNg/b3403c23-8a94-462f-be1f-1f792d604f84
https://www.globenewswire.com/NewsRoom/AttachmentNg/ac04659f-88d2-4062-9ac5-dfaf07ceceb6
https://www.globenewswire.com/NewsRoom/AttachmentNg/d8f96e4e-f508-44d7-8297-3462d489aaf1Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Molecular Instruments and Alpenglow Biosciences Partner to Advance 3D RNA Imaging in Intact Biological Samples
LOS ANGELES & SEATTLE, June 03, 2025--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the innovative HCR™ platform, and Alpenglow Biosciences, a leader in 3D light-sheet microscopy, are excited to announce a partnership that enables high-resolution, three-dimensional RNA imaging in intact biological specimens. By integrating MI's HCR™ Gold RNA-FISH assay with Alpenglow's 3Di™ Hybrid Open-Top Light-Sheet (HOTLS) fluorescent microscope, researchers gain access to a powerful, accessible workflow for visualizing molecular expression patterns in 3D while preserving the native architecture of their samples. This collaboration merges two state-of-the-art technologies into a seamless imaging solution. HCR™ Gold RNA-FISH provides highly specific and sensitive labeling of RNA targets in any sample, including thick tissues and whole-mount specimens. Additionally, the HCR™ platform's small DNA-based amplification reagents enable deep sample penetration and produce strong signals with minimal background, ensuring robust results even in challenging samples. Complementing this, Alpenglow's 3Di™ HOTLS system generates high-resolution 3D reconstructions across a broad range of sample sizes and formats, transforming labeled samples into rich, spatially resolved datasets. Alpenglow further enhances these insights with cutting-edge data processing and AI-driven analysis, enabling a deeper understanding of complex biological systems. "HCR™ products have long enabled researchers to see deeper – delivering gold-standard performance in thick and complex samples, from whole-mount embryos to cleared tissues," said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. "We pioneered protease-free sample preparation to preserve fine structure, and now, with Alpenglow, we're entering a new era: democratizing 3D molecular imaging for the translational community. By combining the precision of HCR™ Gold with the power of open-top light-sheet microscopy, we're opening a window into intact biology – making it possible to explore molecular organization in its native context, at scale." "We are excited to work with the team at Molecular Instruments," said Nick Reder, MD and CEO of Alpenglow Biosciences. "With their high-quality HCR™ Gold reagents and ability to penetrate deep tissue, along with our 3Di Instrument, we will bring a powerful new tool to customers seeking to understand the underlying biology of their tissue specimens with labeling of RNA targets. These tools working together will help researchers and drug development scientists to unlock insights within the tissue to help accelerate their scientific programs." Together, the two platforms eliminate the limitations of conventional 2D histology, which often relies on thin tissue sections and can obscure key biological context. This integrated approach empowers researchers to explore intact samples – such as embryos, organoids, and other delicate 3D structures – without disrupting their morphology. In doing so, scientists can uncover spatial patterns and cellular interactions that would otherwise be lost in serial sections. Designed for modern workflows, HCR™ Gold is fully compatible with tissue clearing and automation, ensuring reproducible, scalable performance across large studies. Alpenglow's 3Di™ HOTLS enhances this capability with a versatile imaging system that supports scan volumes up to 12.5 cm by 7 cm and features a 1 cm working distance – delivering high-throughput, adaptive imaging across diverse research applications. This joint solution is especially impactful in fields such as developmental biology, neuroscience, and immunology – areas where understanding molecular organization in 3D is critical to advancing scientific discovery. By combining the precision of HCR™ Gold with the advanced imaging capabilities of 3Di™ HOTLS, MI and Alpenglow Biosciences are offering deeper insights into complex systems and setting a new standard in molecular profiling. About Molecular Instruments Molecular Instruments® ( is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics. About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at View source version on Contacts Media Contact: Joyce YooAssociate Director of Marketingjoyce@ Steve PembertonSVP Commercial Developmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment2 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson & Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma. In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative (at least 10–5 threshold) and imaging negative throughout five years of post-treatment follow-up.1 Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.3 'This new evidence shows how a single infusion of cilta-cel can help patients survive without disease progression much longer than previously thought possible in this setting, and without any maintenance or subsequent treatment,' said Peter M. Vorhees, M.D., Clinical Professor of Hematology and Oncology at Atrium Health, Levine Cancer Institute at Wake Forest University School of Medicine.* 'In a heavily pre-treated population, a third of patients remained treatment- and progression-free for at least five years.' The Phase 1b/2 CARTITUDE-1 study (n=97) evaluated cilta-cel for the treatment of heavily pre-treated patients with RRMM.1 Patients who remained progression-free for at least five years (n=32) had a median of six prior lines of therapy and included subgroups with high-risk cytogenetics (23.3 percent), extramedullary disease (12.5 percent), triple-class refractory disease (90.6 percent), and penta-drug refractory disease (46.9 percent).1 At a median follow-up of 61.3 months, median overall survival (OS) was 60.7 months (95 percent confidence interval [CI], 41.9, not estimable [NE]), highlighting the depth and durability of response with cilta-cel.1 With an additional ~28 months median follow-up, the safety profile in CARTITUDE-1 was consistent with the known safety profile of cilta-cel, with no new safety signals observed.1 There were two newly reported second primary malignancies (both solid tumours), two additional neurologic events, not related to cilta-cel, including one case each of encephalopathy and taste disorder, four new-onset Grade 3 infections (not related to cilta-cel), and no new Parkinsonism events or cranial nerve palsies.1 'The latest results from the CARTITUDE-1 study mark a major milestone in the treatment of relapsed and refractory multiple myeloma, with a single infusion of cilta-cel delivering unprecedented long-term outcomes,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'In a patient population where median overall survival has traditionally been around one year, it is promising to see many people now living beyond five years - a testament to the transformative potential of cilta-cel.' Additional data from another cilta-cel study, CARTITUDE-4, also presented at the 2025 ASCO Annual Meeting, evaluated PFS and OS versus standard of care (SOC) in prespecified subgroups, including patients with standard and high-risk cytogenetics, extramedullary disease, and by line of therapy (Abstract #7539).2 Results demonstrated that cilta-cel improved PFS and OS across subgroups versus SOC. In patients with standard risk-disease after 1 to 3 prior lines of treatment, PFS curves indicate stability in survival rates.2 'Across our multiple myeloma portfolio and pipeline, we are shifting from treating to progression to treating to cure,' said Jordan Schecter, M.D., Vice President, Research & Development, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'Our focus is to extend patient survival, and based on our expertise of the disease biology, develop treatment regimens with curative potential.' Results will also be presented at the upcoming European Hematology Association (EHA) 2025 Congress. About CARTITUDE-1CARTITUDE-1 (NCT03548207) is a Phase 1b/2, open-label, multicentre study evaluating the efficacy and safety of cilta-cel in adults with relapsed and/or refractory multiple myeloma (RRMM), 99 percent of whom were refractory to the last line of treatment; 88 percent of whom were triple-class refractory, meaning their cancer did not or no longer responds to an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody.4,5 The primary objective of the Phase 1b portion of the study, involving 29 patients, was to characterise the safety and confirm the dose of cilta-cel, informed by the first-in-human study with LCAR-B38M CAR-T cells (LEGEND-2).4 Based on the safety profile observed in this portion of the study, outpatient dosing is being evaluated in additional CARTITUDE studies. The Phase 2 portion of the study is evaluating the efficacy of cilta-cel with overall response as the primary endpoint.4 The study involved patients with heavily pretreated RRMM who historically have an expected median progression-free survival of <6 months and median overall survival of ~1 year.4 About CARTITUDE-4 CARTITUDE-4 (NCT04181827) is the first international, randomised, open-label Phase 3 study evaluating the efficacy and safety of cilta-cel versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, including a PI and an IMiD.6 Patients were randomised to receive either a sequence of apheresis, bridging therapy, lymphodepletion and cilta-cel (n=208) or standard of care (SOC), which included PVd or DPd (n=211).7 The primary outcome measure for the study is progression free survival (PFS), defined as the time from the date of randomisation to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause.6 Safety, overall survival (OS), minimal residual disease (MRD) negativity rate and overall response rate are secondary endpoints.6 About Cilta-cel Cilta-cel is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy that involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR-positive T-cells to eliminate cells that express BCMA.7 BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B-cells and plasma cells.8 The cilta-cel CAR protein features two BCMA-targeting single domains designed to confer high avidity against human BCMA.7 Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.9 In April 2024, the European Commission (EC) approved an indication extension for cilta-cel for the treatment of adults with RRMM who have received at least one prior therapy, including an iMiD and a PI, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. In April 2024, cilta-cel was approved in the U.S. for the second-line treatment of adult patients with relapsed or refractory myeloma who have received at least one prior line of therapy including a PI, an iMiD, and who are refractory to lenalidomide. In December 2017, Janssen Biotech, Inc., a Johnson & Johnson company, entered into an exclusive worldwide licence and collaboration agreement with Legend Biotech USA, Inc., to develop and commercialise cilta-cel.10 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using cilta-cel please refer to the Summary of Product Characteristics.7 In line with European Medicines Agency (EMA) regulations for new medicines and those given conditional approval, cilta-cel is subject to additional monitoring.7 About Multiple Myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.11,12 In multiple myeloma, these plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, often causing bone destruction and other serious complications.13 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.14 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy while remissions become progressively shorter.15,16,17 Whilst some people diagnosed with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney problems.18,19 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at Follow us at Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of cilta-cel. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. * Dr Peter M. Vorhees, M.D., Clinical Professor of Hematology and Oncology at Atrium Health, Levine Cancer Institute at Wake Forest University School of Medicine, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work. ### 1 Voorhees, P. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.2 Sidana, S. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.3 Voorhees, P. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 43, 7507-7505. DOI:10.1200/JCO.2025.43.16_suppl.7507 4 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1). Available at: Study Details | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Last accessed: May 2025.5 Lin Y, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting 2023.6 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE4). Available at: Last accessed: May 2025.7 European Medicines Agency. CARVYKTI (ciltacabtagene autoleucel) Summary of Product Characteristics. Available at: Last accessed: May 2025.8 Cho, et al. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 2018;10(9):1821. 9 Tai, et al. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7(11):1187-1199. 10 Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy. Available at: Last accessed: May 2025.11 Abdi, et al. Drug resistance in multiple myeloma: latest findings on molecular mechanisms. Oncotarget 2013;4(12):2186-2207.12 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: Last accessed: May 2025. 13 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. Available at: Last accessed: May 2025. 14 ECIS. European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at: Last accessed: May 2025.15 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.16 Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.17 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.18 American Cancer Society. What is Multiple Myeloma? Last accessed: May 2025.19 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. Last accessed: May 2025 CONTACT: Media contact: Jenni Mildon jmildon@ +44 7920 418 552 Investor contact: Lauren Johnson investor-relations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
United States Clinical Trial Investigative Site Network Market Competition, Forecast & Opportunities to 2030: Rising Adoption of Decentralized and Hybrid Clinical Trials
The U.S. Clinical Trial Investigative Site Network Market is driven by complex trials, rising chronic disease incidence, and partnerships with site networks enhancing efficiency. Key opportunities lie in decentralized and hybrid trial models, supported by digital tools, with ongoing demand for innovation in patient recruitment and retention. U.S. Clinical Trial Investigative Site Network Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "United States Clinical Trial Investigative Site Network Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The United States Clinical Trial Investigative Site Network Market was valued at USD 2.88 Billion in 2024 and is expected to reach USD 4.51 Billion by 2030, rising at a CAGR of 7.73%. The market is expanding steadily, driven by the growing complexity of clinical trials and the increasing need for specialized infrastructure. Rising incidences of chronic illnesses such as cancer, cardiovascular, and neurological diseases are pushing pharmaceutical and biotech firms to speed up drug development through partnerships with site networks. These networks enhance efficiency through centralized coordination, experienced investigators, and improved patient recruitment. The market is also being shaped by the growing adoption of decentralized and hybrid trial models, supported by digital health tools and remote monitoring technologies. Artificial intelligence and machine learning are being utilized to optimize site selection, enrollment forecasts, and protocol design. With the growing emphasis on precision medicine, investigative networks are adjusting recruitment and operational models to support personalized trial approaches. Key Market Drivers: Rising Number of Clinical Trials and Drug Development Activities An increase in clinical trials and drug development activities is a primary growth driver for the United States Clinical Trial Investigative Site Network Market. Growing investments by pharmaceutical and biotechnology firms in innovative therapies have intensified the demand for clinical trials. As of 2024, the U.S. accounted for over 35% of all global clinical trials, underscoring its leadership in the research landscape. The surge in trials for biologics, gene therapies, immunotherapies, and precision medicine by sponsors such as pharma companies, CROs, and academic institutions has amplified the reliance on investigative site networks. Furthermore, expedited approval pathways for breakthrough drugs have encouraged trial expansion across multiple U.S. regions, reinforcing the role of site networks in accelerating therapeutic development. Key Market Challenges: Patient Recruitment and Retention Difficulties Recruiting and retaining patients remains a persistent hurdle in the United States Clinical Trial Investigative Site Network Market. Recruitment is hampered by limited public awareness, complex eligibility requirements, and safety concerns associated with experimental treatments. Specialized trials, particularly in oncology, rare diseases, and CNS disorders, face difficulties in identifying suitable participants, often delaying study timelines and increasing costs. Retention presents another issue, as patients may discontinue participation due to side effects, time constraints, travel demands, or lack of perceived benefits. These barriers are particularly pronounced for individuals in rural or underserved locations. To mitigate these challenges, site networks are incorporating digital tools like telemedicine, mobile health apps, and wearable technology to simplify participation and maintain engagement. While these tools offer promise, patient enrollment and retention continue to pose significant obstacles, necessitating ongoing innovation to support market growth. Key Market Trends: Rising Adoption of Decentralized and Hybrid Clinical Trials The shift toward decentralized and hybrid clinical trial models is a defining trend in the United States Clinical Trial Investigative Site Network Market. Traditional models often require frequent site visits, which can be burdensome for patients, especially those in remote locations. Decentralized trials leverage telehealth, wearable technology, and mobile applications to allow participants to engage remotely, minimizing the need for in-person visits. Hybrid trials combine on-site and virtual components to offer greater flexibility and accessibility. These models are particularly useful in global or geographically diverse studies. Investigative site networks are increasingly integrating technologies that support decentralized approaches, such as real-time monitoring tools, digital biomarkers, and patient engagement platforms. These innovations improve compliance, streamline data collection, and boost patient retention, offering a more adaptive and efficient framework for clinical research. Key Market Players: PAREXEL International ICON plc IQVIA Holdings Inc. Velocity Clinical Research Inc. Elligo Health Research, Inc. WCG Clinical, Inc. Access Clinical Trials Inc. FOMAT Medical Research, Inc. Charles River Laboratories International, Inc. ePharmaSolutions, Inc. Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.88 Billion Forecasted Market Value (USD) by 2030 $4.51 Billion Compound Annual Growth Rate 7.7% Regions Covered United States Report Scope: In this report, the United States Clinical Trial Investigative Site Network Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: United States Clinical Trial Investigative Site Network Market, By Phase: Phase I Phase II Phase III Phase IV United States Clinical Trial Investigative Site Network Market, By Therapeutic Area: Oncology Cardiology CNS Conditions Pain Management Endocrine Others United States Clinical Trial Investigative Site Network Market, By End User: Pharmaceutical & Biopharmaceutical Companies Medical Device Companies Others United States Clinical Trial Investigative Site Network Market, By Region: North-East Mid-West West South For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Clinical Trial Investigative Site Network Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
